Pictet Asset Management Holding SA Makes New $3.15 Million Investment in Erasca, Inc. $ERAS

Pictet Asset Management Holding SA bought a new stake in Erasca, Inc. (NASDAQ:ERAS) during the first quarter, HoldingsChannel.com reports. The institutional investor bought 208,273 shares of the company’s stock, valued at approximately $3,145,000.

A number of other institutional investors have also modified their holdings of the stock. Neuberger Berman Group LLC raised its stake in shares of Erasca by 11.3% during the fourth quarter. Neuberger Berman Group LLC now owns 12,358 shares of the company’s stock worth $46,000 after purchasing an additional 1,253 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Erasca by 25.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,787 shares of the company’s stock worth $51,000 after purchasing an additional 2,820 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Erasca by 11.1% during the fourth quarter. ProShare Advisors LLC now owns 44,216 shares of the company’s stock worth $164,000 after buying an additional 4,430 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Erasca by 0.8% during the 4th quarter. AQR Capital Management LLC now owns 669,876 shares of the company’s stock worth $2,492,000 after acquiring an additional 5,537 shares in the last quarter. Finally, Captrust Financial Advisors boosted its position in Erasca by 13.6% during the second quarter. Captrust Financial Advisors now owns 54,111 shares of the company’s stock worth $69,000 after purchasing an additional 6,486 shares in the last quarter. Institutional investors and hedge funds own 67.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on ERAS. Wall Street Zen cut Erasca from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Wolfe Research set a $16.00 target price on shares of Erasca in a report on Thursday, June 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Erasca in a research report on Thursday, June 11th. HC Wainwright increased their price objective on shares of Erasca from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Finally, Citigroup reiterated a “buy” rating on shares of Erasca in a research note on Friday, March 13th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $20.11.

More Erasca News

Here are the key news stories impacting Erasca this week:

• Negative Sentiment: Multiple law firms, including Rosen, Schall, Robbins, and Kahn Swick & Foti, are urging investors who bought Erasca shares between January 14, 2025 and April 26, 2026 to seek lead-plaintiff status before the August 10, 2026 deadline, highlighting ongoing securities-fraud litigation risk. Article Title
• Negative Sentiment: The underlying lawsuit focuses on alleged disclosure issues and safety/patent concerns around ERAS-0015, including the patent infringement dispute and reported patient death, which could weigh on investor confidence. Article Title

Erasca Stock Performance

Erasca stock opened at $18.47 on Friday. The company has a 50-day simple moving average of $13.42 and a 200-day simple moving average of $12.28. The firm has a market capitalization of $5.74 billion, a P/E ratio of -19.86 and a beta of 0.66. Erasca, Inc. has a one year low of $1.33 and a one year high of $24.28.

Erasca (NASDAQ:ERAS) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). As a group, sell-side analysts forecast that Erasca, Inc. will post -0.55 earnings per share for the current year.

Erasca Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.